Objective Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to: a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of β-lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best β-lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesclinical medicinepneumologytuberculosismedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance Keywords Tuberculosis Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SC1-PM-09-2016 - New therapies for chronic diseases Call for proposal H2020-SC1-2016-2017 See other projects for this call Sub call H2020-SC1-2016-RTD Funding Scheme RIA - Research and Innovation action Coordinator GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL Net EU contribution € 704 870,67 Address C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MAD 28760 TRES CANTOS MADRID Spain See on map Region Comunidad de Madrid Comunidad de Madrid Madrid Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 704 870,67 Participants (4) Sort alphabetically Sort by Net EU contribution Expand all Collapse all UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET Norway Net EU contribution € 644 072,50 Address HANSINE HANSENS VEG 14 9019 Tromso See on map Region Norge Nord-Norge Troms og Finnmark Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 644 072,50 FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM Germany Net EU contribution € 1 242 417,00 Address PARKALLEE 1-40 23845 Borstel See on map Region Schleswig-Holstein Schleswig-Holstein Segeberg Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 242 417,00 UNIVERSITY OF CAPE TOWN South Africa Net EU contribution € 209 953,75 Address PRIVATE BAG X3 7701 Rondebosch See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 209 953,75 TASK FOUNDATION NPC South Africa Net EU contribution € 3 018 102,08 Address M2 KARL BREMER HOSPITAL MIKE PIENAAR BOULEVARD BELLEVILLE 7530 Cape Town See on map Activity type Other Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 018 102,08